



This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claim 1 (original): A method for the prevention or treatment of visceral pain comprising administering to a patient in need of treatment an effective amount of a compound of formula I-IV:




I



II




III




IV

or a pharmaceutically acceptable salt thereof, wherein n is an integer of from 1 to 4.


Claim 2 (original): A method for preventing or treating gastrointestinal disorders comprising administering to a patient in need of treatment an effective amount of a compound of formula I-IV:




I



II



III



IV

or a pharmaceutically acceptable salt thereof, wherein n is an integer of from 1 to 4.

Claim 3 (original): The method of Claim 1 or 2, wherein the compound is selected from:

(1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1□3□5□)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 α ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 α ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 α)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 α)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
(1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
(1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
(1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
(1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
(1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
(1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,

((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
((2S,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
((2S,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
((2R,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α R,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid,

((2S,4αR,9αR)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
((2S,4αS,9αS)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid, and
((2R,4αS,9αS)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
or a pharmaceutically acceptable salt thereof.

Claim 4 (original): The method according to Claim 1 or 2, wherein the compound is the compound of formula I or a pharmaceutically acceptable salt thereof.

Claim 5 (original): A method for the prevention or treatment of visceral pain comprising administering to a patient in need of treatment an effective amount of (1α,3α,5α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid or a pharmaceutically acceptable salt thereof.

Claim 6 (original): A method for preventing or treating gastrointestinal disorders comprising administering to a patient in need of treatment an effective amount of (1α,3α,5α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid or a pharmaceutically acceptable salt thereof.

Claim 7 (original): The method according to any one of Claim 1 to 6, wherein the disorder is functional bowel disorder or inflammatory bowel disease.

Claim 8 (original): The method according to Claim 7, wherein the functional bowel disorder is gastro-esophageal reflux, dyspepsia, irritable bowel syndrome or functional abdominal pain syndrome.

Claim 9 (original): The method according to Claim 7, wherein the inflammatory bowel disease is Crohn's disease, ileitis or ulcerative colitis.

Claim 10 (original): A method according to any one of Claims 1, 3, 4 or 5, wherein the disorder is associated with dysmenorrhea pain, pelvic pain, cystitis pain and pancreatitis.


Claim 11 (original): A pharmaceutical composition for the treatment or prevention of visceral pain and GI disorders comprising a compound of formula I-IV.

Claim 12 (original): The pharmaceutical composition according to claim 11 comprising (1 α ,3 α ,5 α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid.

Claim 13 (original): The pharmaceutical composition according to claim 11 or 12 for treating or preventing disorders selected from the group consisting of functional bowel disorders such as gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, functional abdominal pain syndrome, or inflammatory bowel diseases such as Crohn's disease, ileitis or ulcerative colitis, or disorders associated with dysmenorrhea pain, pelvic pain, cystitis pain and pancreatitis.

Claim 14 (original): The pharmaceutical composition according to any one of claims 11 to 13, which is under a form suitable for oral administration.

Claim 15 (new): A method for treating irritable bowel syndrome comprising administering to a patient in need of treatment an effective amount of a compound of formula I-IV:



or a pharmaceutically acceptable salt thereof, wherein n is an integer of from 1 to 4.

Claim 16 (new): The method of Claim 15, wherein the compound is selected from:

- (1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
- (2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
- (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,

(1 α ,3 α ,5 α)-3-Aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 α ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 α ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 α)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 α)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,7 α ,9 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,

((3 α S,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
((2S,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
((2S,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
((2R,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α R,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
((2S,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,
((2S,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid, and
((2R,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)- acetic acid,

Nov-05-2003 12:37pm From-
10/056,298

PATENT PFIZER ANN ARBOR MI

- 9 -

7346222928

T-342 P.012/014 F-854
A0000506

or a pharmaceutically acceptable salt thereof.

Claim 17 (new): The method according to Claim 15, wherein the compound is the compound of formula I or a pharmaceutically acceptable salt thereof.

Claim 18 (new): A method for treating irritable bowel syndrome comprising administering to a patient in need of treatment an effective amount of $(1\alpha,3\alpha,5\alpha)$ -3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid or a pharmaceutically acceptable salt thereof.

Claim 19 (new): A pharmaceutical composition for the treatment of irritable bowel syndrome comprising a compound of formula I-IV.

Claim 20 (new): The pharmaceutical composition according to claim 19 comprising $(1\alpha,3\alpha,5\alpha)$ -3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid.